Outcomes by product
GLP-1 outcomes compared, product by product
Stop comparing brand names. Compare what each GLP-1 medication actually delivers — how hard it crushes hunger, how fast the scale moves, and what side effects to plan for in your first 12 weeks.
How hard each GLP-1 turns down hunger
- StrongWegovyWeekly injection — FDA approved for weight loss
Most patients report meaningful appetite suppression by the 0.5 mg dose, with hunger dropping further as you titrate to the 1.7 mg and 2.4 mg maintenance doses.
- Very strongZepboundWeekly injection — dual GIP/GLP-1 agonist
Dual GIP/GLP-1 action suppresses hunger more aggressively than semaglutide for most patients. Many report needing to set reminders to eat by week 8.
- StrongCompounded SemaglutideWeekly injection — pharmacy compounded
Same active molecule as Wegovy, so appetite suppression is comparable when dosed identically. Some compounded formulations include B12, which does not change efficacy.
- Very strongCompounded TirzepatideWeekly injection — pharmacy compounded
Dual-agonist appetite suppression matches branded Zepbound when titration is matched. Expect a sharp drop in cravings between weeks 4–8.
- ModerateOral SemaglutideDaily oral tablet — for needle-averse patients
Oral bioavailability is lower than injected semaglutide, so appetite suppression is real but less dramatic at equivalent dosing.
- ModerateSaxendaDaily injection — first-generation GLP-1
Shorter half-life than semaglutide or tirzepatide, so appetite effects fluctuate during the day. Less hunger suppression overall.
When you'll see results — and how much
- WegovyWeekly injection — FDA approved for weight loss
- First results
- Week 4–8
- Avg loss at 6 mo
- 8–12% of body weight
- Avg loss at 12 mo
- 14–15% of body weight
STEP trial data showed an average 14.9% reduction at 68 weeks on the 2.4 mg dose. Weight loss tends to be linear through month 9, then flattens.
- ZepboundWeekly injection — dual GIP/GLP-1 agonist
- First results
- Week 2–4
- Avg loss at 6 mo
- 12–15% of body weight
- Avg loss at 12 mo
- 18–22% of body weight
SURMOUNT-1 reported a 20.9% average loss at the 15 mg dose over 72 weeks — the highest of any approved GLP-1 to date.
- Compounded SemaglutideWeekly injection — pharmacy compounded
- First results
- Week 4–8
- Avg loss at 6 mo
- 8–12% of body weight
- Avg loss at 12 mo
- 12–15% of body weight
Real-world telehealth data tracks closely with STEP trial outcomes when patients reach a 2.0–2.4 mg maintenance dose.
- Compounded TirzepatideWeekly injection — pharmacy compounded
- First results
- Week 2–4
- Avg loss at 6 mo
- 11–14% of body weight
- Avg loss at 12 mo
- 16–20% of body weight
Compounded tirzepatide commonly delivers faster early loss than semaglutide thanks to stronger appetite effects.
- Oral SemaglutideDaily oral tablet — for needle-averse patients
- First results
- Week 6–10
- Avg loss at 6 mo
- 5–8% of body weight
- Avg loss at 12 mo
- 8–11% of body weight
Expect a slower, gentler curve. Many programs use oral as a stepping stone before injection.
- SaxendaDaily injection — first-generation GLP-1
- First results
- Week 4–6
- Avg loss at 6 mo
- 5–7% of body weight
- Avg loss at 12 mo
- 7–9% of body weight
Effective but outclassed by newer molecules. Often used when insurance prefers it or for patients sensitive to weekly dosing.
What to plan for in your first 12 weeks
- Moderate burdenWegovyWeekly injection — FDA approved for weight loss
- Nausea
- Constipation
- Fatigue
- Sulfur burps
Side effects peak during dose escalation. Slow titration (staying 8+ weeks at each dose) reduces nausea significantly.
- Moderate burdenZepboundWeekly injection — dual GIP/GLP-1 agonist
- Nausea
- Diarrhea
- Constipation
- Burping
Side effect profile is similar to semaglutide but with slightly more GI motility issues. Hydration and fiber matter more on tirzepatide.
- Moderate burdenCompounded SemaglutideWeekly injection — pharmacy compounded
- Nausea
- Constipation
- Fatigue
- Injection-site reaction
Side effects mirror Wegovy. Pay attention to your compounding pharmacy's source and sterility documentation.
- Moderate burdenCompounded TirzepatideWeekly injection — pharmacy compounded
- Nausea
- Diarrhea
- Reflux
- Fatigue
Similar to branded Zepbound. Some patients report stronger reflux on tirzepatide than semaglutide; smaller meals help.
- Lower burdenOral SemaglutideDaily oral tablet — for needle-averse patients
- Mild nausea
- Bloating
- Decreased appetite
Must be taken on an empty stomach with ≤4 oz of water and 30 minutes before food — adherence is the real challenge.
- Higher burdenSaxendaDaily injection — first-generation GLP-1
- Nausea
- Vomiting
- Diarrhea
- Headache
Daily dosing means daily exposure to side effects rather than the once-weekly peak/trough pattern of newer GLP-1s.
Best fit by patient situation
- WegovyWeekly injection — FDA approved for weight loss
Patients with commercial insurance who want the FDA-approved branded product and a predictable supply chain.
Heads up — Watch out: Insurance prior authorization can take 4–6 weeks; brand-name supply has improved but is not guaranteed.
- ZepboundWeekly injection — dual GIP/GLP-1 agonist
Patients targeting >15% total body weight loss, especially those with insulin resistance.
Heads up — Watch out: Highest list price of any GLP-1; insurance coverage is the deciding factor for most.
- Compounded SemaglutideWeekly injection — pharmacy compounded
Patients without GLP-1 insurance coverage who want semaglutide at a predictable monthly cost.
Heads up — Watch out: FDA enforcement discretion is evolving. Choose a provider that documents the pharmacy and offers a transition plan.
- Compounded TirzepatideWeekly injection — pharmacy compounded
Patients chasing maximum weight loss without brand-name pricing.
Heads up — Watch out: Same regulatory uncertainty as compounded semaglutide. Confirm the pharmacy and the dose-escalation protocol.
- Oral SemaglutideDaily oral tablet — for needle-averse patients
Patients who can't or won't inject, or who want to test tolerance before committing to weekly shots.
Heads up — Watch out: Skipping the empty-stomach window destroys absorption. Daily discipline matters more than dose.
- SaxendaDaily injection — first-generation GLP-1
Patients whose insurance covers Saxenda but not Wegovy or Zepbound.
Heads up — Watch out: Daily injections become a long-term adherence burden for most patients.
Not sure which outcome to prioritize?
Most patients pick a medication based on a single goal — fastest loss, lowest side effects, or insurance coverage. Our quiz matches your priorities to the right product and provider in under two minutes.
Take the 2-minute match quizFAQ
GLP-1 outcome questions, answered
- Tirzepatide (Zepbound and compounded tirzepatide) is the most aggressive at suppressing appetite because it activates both the GIP and GLP-1 receptors. Most patients notice a sharper drop in hunger by week 4–6 versus semaglutide.